FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	$D \subset$	20549
vasilliquui,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours nor rosnons	o: 0.E								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Zanganeh Mahkam (Last) (First) (Middle)					2. Issuer Name and Ticker or Trading Symbol Pulse Biosciences, Inc. [PLSE] 3. Date of Earliest Transaction (Month/Day/Year) 05/25/2023								(Ch	eck all appli X Directo	or (give title		on(s) to Iss 10% Ow Other (s below)	/ner	
3957 POINT EDEN WAY					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	RD C.	A	94545												iled by More	ne Reporting Person lore than One Reporting			
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication														
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										ed to									
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				ate	Execution Date,		Code (Instr. 5)				Benefici	es ally Following	Form: (D) or I		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code			v	Amount	(A) c (D)	Price	Transaci (Instr. 3	ction(s)			(iiisti. 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Co	ansacti ode (Ins			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Co	ode	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$5.95	05/25/2023			A		20,000		(1)	05/	/25/2033	Common Stock	20,000	\$0	20,000		D		
Stock Option (right to buy)	\$5.95	05/25/2023			A		20,168		(2)	05/	/25/2033	Common Stock	20,168	\$0	20,168		D		

Explanation of Responses:

- 1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on June 25, 2023.
- 2. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2023.

/s/ Kenneth B. Stratton, as Attorney-in-Fact 06/06/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.